OrganaBio Expands to the San Francisco Bay Area with New PBMC Processing Laboratory in Hayward, California
OrganaBio, LLC, a leading provider of human research- and clinical-grade cellular starting materials and clinical trial support services today announced the opening of its newest cell processing and cryopreservation facility in Hayward, California, further strengthening its nationwide network supporting cell therapy developers and clinical trial sponsors.
GaiaGift Triples Physician Network to Ethically Collect Increasing Volumes of Birth Tissues Needed for the Rapidly Burgeoning Development of Cell and Gene Therapies
GaiaGift, LLC (a wholly owned subsidiary of OrganaBio, LLC) a leader in the field of birth tissue collection, announces the expansion of its esteemed physician network, offering more opportunities for donors to participate in its remarkable donation program supporting the development of novel cell and gene therapies. GaiaGift's mission is to empower families to make a positive impact on healthcare by ethically donating otherwise discarded birth tissue, contributing to groundbreaking medical research and helping patients in need. Since its inception in 2019, GaiaGift has collected 240 birth tissue units, and the recent tripling of its physician network across South Florida, to 40 OB/GYN professionals across multiple practices, will rapidly increase donor recruitment and collections to meet scaling industry needs.
OrganaBio Expands Its Operations to the West Coast of the U.S.
OrganaBio, LLC, announces the opening of a new laboratory facility in Irvine, California, further expanding its reach and capabilities from the southeast to the west coast. The new facility will offer support services to clinical trial sponsors and CROs, including patient sample processing, analytical testing, cryopreservation, and storage.
Meet with the OrganaBio executives in-person at The Cell & Gene Meeting on the Mesa
The 2022 Cell & Gene Meeting on the Mesa annual conference will be held in Carlsbad, California, on October 11-13, 2022, bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. Meet with the OrganaBio team to learn about our reliable supply of high-quality, ethically sourced tissue and cellular raw materials with clear paths to clinical translation, and the advanced processing and characterization capabilities we offer to speed up novel therapeutic development.
With the Commencement of GMP Manufacturing Operations, OrganaBio’s CDMO Offers the Cell Therapy Industry Ready Access to Flexible Manufacturing Solutions and Clinical Grade Cellular Raw Materials
OrganaBio, LLC, announces initiation of GMP manufacturing operations at its new cell therapy manufacturing facility, launching a new paradigm in contract and development manufacturing. Acknowledging the need for custom solutions for therapeutics developers, the company will not only leverage its tissue supply chains to manufacture clinical grade tissue and cellular raw materials derived from perinatal tissues and adult apheresis products for partners, but will also offer contract-, self-, and hybrid-manufacturing options within the facility.
OrganaBio Adds Perinatal and Adult Tissues for Clinical Manufacturing to its Portfolio of Products for Allogeneic Cell Therapy Development
OrganaBio, LLC (“OrganaBio”) is expanding its product portfolio with the addition of current Good Manufacturing Practices (cGMP)- and current Good Tissue Practices (cGTP)-compliant perinatal umbilical cord blood and leukopak products. Obtained from fully consented donors, under IRB-approved protocols, with comprehensive testing and supporting documentation to meet the regulatory requirements of the US FDA and other regulatory agencies, OrganaBio’s cGMP compliant products further deliver on OrganaBio’s commitment to providing high quality critical starting materials to cell therapy and cancer immunotherapy developers. Marketed under the HematoPAC™-GMP and LeukoPAC™-GMP brands, these products are a source of hematopoietic stem cells (HSCs) and lymphoid- and myeloid-derived immune cells, including T, NK, T-reg, gamma delta T cells, macrophages, and B cells, which are critical raw materials for allogeneic regenerative medicine, cell therapy, and immunotherapy development and manufacturing.
OrganaBio Announces the Addition of Adult Peripheral Blood-Derived Leukopaks to its Portfolio of Products for Cell Therapy Development
OrganaBio, LLC (“OrganaBio”) announces the launch of adult peripheral blood-derived products, including vialed peripheral blood mononuclear cells (PBMCs) and whole leukopaks (LeukoPAC™). These products contain high concentrations of PBMCs, such as T cells, NK cells, B cells and monocytes, which are critical raw materials for immunotherapy research and allogeneic cell therapy development and manufacturing. OrganaBio’s unique supply chain and manufacturing capabilities enable it to process PBMCs within hours of collection to ensure delivery of high-quality starting material to researchers and therapeutics developers.
